Occidental Asset Management LLC Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Occidental Asset Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,774 shares of the biopharmaceutical company’s stock after buying an additional 544 shares during the quarter. Occidental Asset Management LLC’s holdings in Pfizer were worth $399,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. LGT Group Foundation boosted its holdings in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after acquiring an additional 18,274 shares during the last quarter. ORG Partners LLC raised its holdings in shares of Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares during the period. Kempner Capital Management Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at about $2,439,000. Commerzbank Aktiengesellschaft FI increased its position in Pfizer by 29.1% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 342,361 shares of the biopharmaceutical company’s stock worth $9,579,000 after purchasing an additional 77,073 shares in the last quarter. Finally, First Foundation Advisors raised its holdings in Pfizer by 15.3% in the first quarter. First Foundation Advisors now owns 155,951 shares of the biopharmaceutical company’s stock valued at $4,328,000 after buying an additional 20,670 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 1.3 %

NYSE:PFE opened at $29.46 on Wednesday. The company has a market cap of $166.94 billion, a PE ratio of -491.00, a P/E/G ratio of 1.30 and a beta of 0.67. The business’s 50 day moving average is $29.02 and its two-hundred day moving average is $28.41. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.92.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.70%. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PFE shares. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.